What Is the Average Weight Loss on Mounjaro?

Last reviewed: July 10, 2026

Last updated: July 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Tirzepatide, a dual GLP-1 and GIP receptor agonist, produced average weight loss of 15-22% of body weight in clinical trials lasting 68 weeks. Real-world outcomes depend on your genetics, commitment to lifestyle changes, and how your body responds during dose escalation. Understanding what to expect helps you set realistic goals and stay motivated throughout your treatment journey.

Clinical Trial Results for Tirzepatide Weight Loss

The SURMOUNT trials, which tested tirzepatide efficacy and safety, enrolled over 4,500 adults with obesity or overweight with weight-related conditions. Participants receiving the highest maintenance doses achieved average weight loss ranging from 15% to 22% of their starting body weight over 68 weeks. Notably, patients on tirzepatide lost significantly more weight compared to those receiving standard GLP-1 therapy or placebo, demonstrating the dual-action mechanism's strength.

Weight loss occurred gradually rather than overnight. Most participants experienced noticeable reductions in appetite and food cravings within the first 2-4 weeks, with measurable scale changes appearing around week 4-6. The steady downward trend continued through month 12 and beyond, with many patients reaching their lowest weight around the 16-week mark of treatment.

Why Individual Tirzepatide Results Vary Widely

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, and GIPR — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Lifestyle factors amplify or reduce tirzepatide's effects. Patients who combine the injection with consistent exercise, balanced nutrition, and adequate sleep typically lose 5-10% more body weight than those relying on medication alone. Your starting weight, age, insulin sensitivity, and adherence to the escalation schedule also shape your final outcome.

Tirzepatide Dosing and Weight Loss Progression

Tirzepatide treatment begins at a low dose—typically 2.5 mg weekly—to allow your body to adjust and minimize nausea or gastrointestinal side effects. Every 4 weeks, your dose increases by 2.5 mg steps, moving through 5 mg, 7.5 mg, 10 mg, and up to 15 mg as your maintenance level. Your PlexusDx provider monitors your response and adjusts the schedule based on tolerance and weight loss progress.

Higher maintenance doses correlate with greater average weight loss, but not everyone requires the maximum 15 mg dose. Many patients achieve their target weight loss at 10 mg or 12.5 mg, where side effects remain minimal and sustainability is highest. PlexusDx uses the phrase 'Your dose may need to go up. Your price won't'—meaning your monthly cost remains flat regardless of dose level, starting at $289/month for compounded tirzepatide injection.

Comparing Tirzepatide to Other GLP-1 Weight Loss Medications

Standard GLP-1 agonists like semaglutide produce average weight loss of 10-17% of body weight, while tirzepatide's dual receptor activation delivers the higher 15-22% range. This difference stems from tirzepatide's action on both GLP-1 and GIP pathways, which together suppress appetite more powerfully and enhance insulin secretion. For patients seeking maximum weight loss potential, tirzepatide represents a stronger option backed by robust trial evidence.

PlexusDx also offers compounded semaglutide injection (starting at $189/mo (or $149/mo on the 6-month plan)) and GLP-Squared Injection—a dual compound combining semaglutide and tirzepatide (starting at $289/month)—for patients whose genetics or preferences favor different approaches. Your Precision Peptide Genetic Test results can guide which medication aligns with your peptide-pathway profile.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $289/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the typical amount of weight loss I can expect with tirzepatide?

Clinical trials show average weight loss of 15-22% of body weight over 68 weeks with tirzepatide. Your individual result depends on genetics, lifestyle adherence, dose escalation tolerance, and starting weight. Most patients see measurable changes by week 6 and continue losing weight through month 12 of treatment.

How long does it take to see weight loss results on tirzepatide?

Many patients notice appetite suppression within 2-4 weeks of starting tirzepatide. Visible scale changes typically appear around week 4-6, with steady weight loss continuing through the dose escalation phase. Maximum weight loss is usually reached around week 16 and maintained thereafter with continued treatment.

Does PlexusDx tirzepatide cost more if I need a higher dose?

No. PlexusDx compounded tirzepatide injection starts at $289/mo (or $249/mo on the 6-month plan) and remains that flat price regardless of your dose level—whether you maintain 7.5 mg or escalate to 15 mg. This pricing applies across all three commitment tiers, with your dose adjusted by your provider based on tolerance and results.

Is compounded tirzepatide from PlexusDx as effective as brand-name Mounjaro?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What genetic factors affect my tirzepatide weight loss results?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GLP1R (rs6923761), and GIPR (rs1800437)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Average Weight Loss On Ozempic
• Mounjaro For Weight Loss 2
• Weight Loss Mounjaro
• Mounjaro Weight Loss By Week

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.